Innovating Against Pre-eclampsia

Pre-eclampsia is a cause of maternal and infant morbidity.

A conversation with Dr. Tania Kamphaus, Associate Vice President, Science Partnerships and Director of Patient Engagements at FNIH (Foundation for the National Institutes of Health regarding blood testing in the first trimester to detect and the development of medications for treatment of early onset pre-eclampsia.

Pre-eclampsia affects 5-8 % of pregnancies in the US with Black Americans 60% more likely to develop pre-eclampia. In addition, the ethical considerations of pharmaceutical testing on pregnant women and racial health disparities of pre-eclampsia among Black Americans.

Is the first trimester testing for early onset pre-eclampsia reliable? Should medications that are being developed be given to pregnant women? And are there long term residual effects for the newborn.

These advancements have the potential to change the landscape of prenatal care